U.S. markets close in 32 minutes
  • S&P 500

    4,585.94
    -76.91 (-1.65%)
     
  • Dow 30

    35,402.57
    -509.24 (-1.42%)
     
  • Nasdaq

    14,562.01
    -331.75 (-2.23%)
     
  • Russell 2000

    2,115.82
    -46.64 (-2.16%)
     
  • Crude Oil

    85.77
    +1.95 (+2.33%)
     
  • Gold

    1,813.80
    -2.70 (-0.15%)
     
  • Silver

    23.58
    +0.67 (+2.91%)
     
  • EUR/USD

    1.1329
    -0.0081 (-0.71%)
     
  • 10-Yr Bond

    1.8650
    +0.0930 (+5.25%)
     
  • GBP/USD

    1.3592
    -0.0055 (-0.40%)
     
  • USD/JPY

    114.6160
    +0.0360 (+0.03%)
     
  • BTC-USD

    41,624.87
    -659.20 (-1.56%)
     
  • CMC Crypto 200

    992.38
    -17.01 (-1.69%)
     
  • FTSE 100

    7,563.55
    -47.68 (-0.63%)
     
  • Nikkei 225

    28,257.25
    -76.27 (-0.27%)
     

While shareholders of SpringWorks Therapeutics (NASDAQ:SWTX) are in the black over 1 year, those who bought a week ago aren't so fortunate

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

It hasn't been the best quarter for SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shareholders, since the share price has fallen 16% in that time. While that might be a setback, it doesn't negate the nice returns received over the last twelve months. After all, the share price is up a market-beating 73% in that time.

Although SpringWorks Therapeutics has shed US$228m from its market cap this week, let's take a look at its longer term fundamental trends and see if they've driven returns.

Check out our latest analysis for SpringWorks Therapeutics

Given that SpringWorks Therapeutics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually expect strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

earnings-and-revenue-growth
earnings-and-revenue-growth

If you are thinking of buying or selling SpringWorks Therapeutics stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

It's nice to see that SpringWorks Therapeutics shareholders have gained 73% over the last year. Unfortunately the share price is down 16% over the last quarter. Shorter term share price moves often don't signify much about the business itself. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Take risks, for example - SpringWorks Therapeutics has 2 warning signs we think you should be aware of.

But note: SpringWorks Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.